TD’s Q3 earnings jump on Canada and capital markets, but U.S. AML overhang remains

What happened

TD reported sharply higher quarterly earnings, driven by strong growth in Canadian banking and capital markets, alongside lower provisions for soured loans. The results highlight the resilience of TD’s non-U.S. businesses, which continue to deliver solid performance even as the U.S. franchise operates under an OCC-imposed asset limitation. While the headline numbers are encouraging, they do not address the core regulatory uncertainty: the ongoing U.S. AML remediation and the timing of validation and acceptance. The master report’s WAIT rating is based on that U.S. overhang, and this earnings report provides no new information on remediation progress. Consequently, the positive earnings surprise may bolster sentiment but does not resolve the key gating factor for long-term value.

Implication

The better-than-expected earnings from Canadian banking and capital markets demonstrate that TD’s diversified model can generate growth outside the constrained U.S. segment, which partially offsets the earnings drag from U.S. remediation costs. However, the U.S. asset cap and permissioning regime remain intact, and without visible progress on internal audit validation or regulator acceptance, the timeline for lifting constraints is still uncertain. The lower loan-loss provisions may reflect a benign credit environment, but that could shift if the economic backdrop deteriorates, adding another layer of risk. For long-term investors, the key remains whether TD can convert remediation milestones into a removal of the U.S. growth restrictions; this earnings report does not change that calculus. Therefore, the WAIT rating remains appropriate, and a more attractive entry price near $110 or a clear U.S. validation disclosure would be needed to upgrade the thesis.

Thesis delta

The earnings strength in non-U.S. segments slightly improves the earnings resilience component of the thesis, but it does not alter the central premise that U.S. AML remediation and asset limitation are the dominant value drivers. The master report’s WAIT rating and price targets remain unchanged, as no new information on U.S. validation or regulatory acceptance was provided. The positive results may reduce downside risk in the near term, but the thesis still hinges on regulatory progress.